| Project/Area Number |
19K18079
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55020:Digestive surgery-related
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
Watanabe Shuichi 東京医科歯科大学, 東京医科歯科大学病院, 助教 (20771827)
|
|---|
| Project Period (FY) |
2021-03-01 – 2024-03-31
|
| Project Status |
Completed (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2021: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2020: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 膵癌 / エピゲノム / 化学療法 / KDM6A / がん抑制遺伝子 / 癌サブタイプ |
|---|
| Outline of Research at the Start |
①臨床検体によるKDM6A発現の解明
②KDM6A KO/強制発現株におけるKDM6Aの生物学的意義の解明
③KDM6A KO/強制発現株におけるエピゲノム修飾因子の変化の解明
④臨床検体を用いたKDM6A変異がもたらす癌ヘテロ性の解明
⑤KDM6A不活化サブタイプに対する新規治療法の解明
|
| Outline of Final Research Achievements |
In this study, we examined the clinical significance of KDM6A expression using public databases and clinical specimens, and performed functional analysis in human pancreatic cancer cell lines. The study revealed that DM6A inactivation is associated with (1) K poor prognosis pancreatic cancer subtype, (2) malignant transformation of pancreatic cancer cell lines, (3) H3K27ac reduction in the promoter region of tumor suppressor genes, and (4) HDAC inhibitors have specific effects.
|
| Academic Significance and Societal Importance of the Research Achievements |
肝胆膵領域の難治癌においてサブタイプを決定づけるエピゲノム修飾遺伝子の変異およびその分子生物学的機能についてトランスレーショナルリサーチによって解明することができ、治療薬開発につながる知見が得られた。
|
